CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.

ABSTRACT: Trastuzumab is regarded as the primary therapy for patients with HER2-enriched breast cancer, but the pathological complete response for advanced cases is less than 30%. The underlying mechanism of trastuzumab resistance remains unclear and there are currently no conclusive biomarkers for patient response to trastuzumab. Identifying predictive biomarkers for trastuzumab response may allow treatments to be individually tailored and optimized multi-target therapies may be developed. CTMP activates AKT signaling in breast cancer and over-activation of AKT has been reported to contribute to trastuzumab resistance. In this study, we examined samples from 369 patients to investigate the correlation between CTMP expression level and patient outcome. Elevated CTMP expression was correlated with ad

SUBMITTER: Chen YC 

PROVIDER: S-EPMC5444696 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature